FIGURE 1.

Eltanexor inhibits HCMV lytic replication in HFFs in a dose-dependent manner. (A) Structure of Eltanexor (KPT-8602). (B) Effects of Eltanexor on cell viability were assayed at 72 h post treatment (hpt). HFFs were treated with Eltanexor at indicated concentrations or vehicle (DMSO, 0 μM). Cell viability was analyzed by a MTS-based colorimetric assays at 72 hpt. Data is presented as% of cell viability relative to vehicle control (indicated by 0 μM). Values represent mean ± SEM; n = 5. Statistical analyses were performed between indicated concentrations and 0 μM. ^∗p < 0.05, ^∗∗p < 0.01. (C) 50% cytotoxic concentration (CC50) is determined at 14.06 mM based on the results of cell viability assays according to non-linear trajectory analysis using GraphPad Prism. (D) Eltanexor inhibits the production of infectious virions in a dose-dependent manner. HFFs were infected with HCMV at a MOI = 1 and treated with the indicated concentrations of Eltanexor. Culture supernatants were collected at 96 hpi and further titrated by a TCID₅₀ method. Values represent mean ± SEM; n = 3. (E) Eltanexor inhibits viral protein synthesis in a dose-dependent manner. Cells were infected with HCMV at a MOI = 1 and then treated with DMSO or Eltanexor at the indicated concentrations for 72 h. Cell lysates were collected and viral protein expression was assayed by immunoblot for the following proteins: IE2, pp52, pp71, and pp65. Intensity values of viral protein bands were analyzed by Amersham Imager 600 analysis software. The experiments were repeated three times.